Poitou et al., Efficacy and safety of setmelanotide, a melanocortin-4 Recepr agonist, in patients with Bardet-Biedl syndrome and Alstrm syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
Uit verschillende wetenschappelijke studies blijkt dat volwassenen met diabetes die semaglutide gebruiken, ongeveer dubbel zoveel kans hebben om NAION te ontwikkelen in vergelijking met niet-gebruikers
Semaglutide works by attaching to GLP-1 receptors in the body
Instead, theyre exploring approaches that combine responsible prescribing, clinical oversight, and lifestyle support to improve outcomes while managing utilization and costs
doi: 10.1016/j.drugalcdep.2021.108614 25 Investigators AOURP